Chris Strouse

University of Iowa; Myeloma, Lymphoma and BMT

[Raj Chakraborty @rajshekharucms]

I used this slide in a recent presentation to highlight that the question of CAR T➡️BsAb vs BsAb ➡️CAR T sequencing in #Myeloma can't be reliably answered by retrospective studies. It's similar to how retrospective studies mostly show OS benefit with upfront ASCT but no RCT has shown that since VRD! This is often a nuanced (and long) discussion with patients!
@HealthTree

[ArtButMakeItSports @ArtButSports]

The Martyrdom of Saint Lawrence, by Jean-Baptiste de Champaigne, 1660, 📸 by @sizqui

[Chris Strouse @strouse_chris]

@End_myeloma I have always wondered why there was never a large phase 3 Kd vs KPd study. The first report of KPd I know of was from 2015, so it's not like there wasn't plenty of time. Do you have any insight into that?

[Chris Strouse @strouse_chris]

@End_myeloma Do you think it is regulators that will be the barrier to CAR-T control arms, or is it the sponsors who will be reluctant to design trials with CAR-T control arms? I have always assumed it will be the latter

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

MagnetisMM-3 in 🇺🇸 cohort: with optimal supportive care, how well can bsAbs work in myeloma?

Answer (albeit n=47): Phenomenally!

DOR >3 yrs with elra monoTx in largely TC-refractory 🇺🇸pts 🤯 Looking at curve, probably an underestimate.

Kudos @AjayNookaMD @NoopurRajeMD et al!

[Al Garfall @AlGarfall]

@Rfonsi1 was kind enough to let me guest author a post in his Substack arguing for tec>cilta-cel in 2nd-line MM therapy as a rebuttal to his prior post arguing the opposite. I hope #mmsm finds this to be a thoughtful exchange. Link below.

[ArtButMakeItNow @artbutnow]

The Garden of Earthly Delights (detail), by Hieronymus Bosch, 1480-1505, 📸 by @alexbrandon

[Chris Strouse @strouse_chris]

@rajshekharucms @RaabMarc @MyMKaiser @ESHaematology Was there any discussion of using the new high risk definitions in this pathway?

[Chris Strouse @strouse_chris]

@rajshekharucms @TAkhlagh Ah very nice, the results of Manni's SPOTLIGHT study will add to knowledge of the shifting natural history of SMM

https://t.co/0LYU2q0MXT

[Chris Strouse @strouse_chris]

@calliecoombsmd @RahulBanerjeeMD @IDEOlogyHealth Wow were the cowboy hats provided? Or was it being your own cowboy hat?

[ArtButMakeItSports @ArtButSports]

Self-Portrait (rotated), potential sketch for The Creation of Adam, by Michelangelo, late 15th//early 16th c

[Chris Strouse @strouse_chris]

@Papa_Heme @MyelomaAmateur Outfits on point boys. Reminds me of this

[Chris Strouse @strouse_chris]

@RahulBanerjeeMD @YiLinMDPhD But is it no difference for palsies, underpowered for PKS, with possible signal?

[Luciano J Costa @End_myeloma]

We have now 3 CT with T-cell redirecting therapy vs. Triples in 1-3 prior LOT in MM with OS superiority. I don't consider acceptable to start randomized trials with DPd/Kd/EPd/etc control when we have proven superior "established therapy with clinical benefit". #mmsm

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our viewpoint published @JAMA_current #MedEd

Abstract Factory—Research Culture Harming Medical Education

The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.

➡️https://t.co/IMBhy45L1K

@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG

[Science News @SciencNews]

Mass abstract submissions in Medical education have led to inflated metrics, less meaningful research, and misaligned incentives for trainees and institutions.

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🎤🧬 Dr. Hira Shaikh @hiragss from @uihealthcare presenting
“Updates in AL Amyloidosis Trials: Anselamimab & Birtamimab”

📊💡 Very informative session at the 3rd Regional Multidisciplinary Amyloid Symposium – Kansas City!
#Amyloidosis #mmsm #myeloma #medtwitter #MedEd #USMIRC @US@USMIRCNEWS @US_HMC @OncoAlert @MedwatchKate @Larvol

[Chris Strouse @strouse_chris]

@MyelomaTeacher @End_myeloma @CoMMitTrials @grpetersen1 @ldandersonjr @bhemato @CBCIDocs @TMSchmidtMD @RahulBanerjeeMD @SusanBal9 That’s what’s happening in the aMMbition study:

https://t.co/dJBM4isLGW

[Ajay Major, MD, MBA @majorajay]

Discharge HD-MTX when level <0.30 #ASH25
- 117 pt encounters, 62% met early d/c criteria
- no persistent AKI or LFTs abnormalities
- more cytopenias w/ early d/c, but no admissions for cytopenias
- fewer admit days w/ early d/c
Can d/c w/ 3d leucovorin/Nabicarb. #lymsm #leusm

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

My top 8 myeloma/amyloidosis #ASH25 abstracts @ASH_hematology #mmsm
8⃣LimiTec: Limited Duration Teclistamab (Abstract #292744 - Razzo et al. @AlGarfall )

➡️Can we stop bispecifics after deep response? Early data says YES!

➡️6-mo FFP: 77%, 12-mo FFP: 73%

➡️Similar outcomes in prior BCMA-directed therapy pts

➡️Talquetamab rescue worked in 3/3 pts

🔗 https://t.co/koAo9N2tCn